DBV Technologies

DBV Technologies

DBV Technologies

DBV Technologies focuses on the development of innovative products for the diagnosis and treatment of food allergies.
Founded
2002
Raised
$309.7M
Follow us
Alexa global traffic share
Latest funding Show all
$281,500,000
Post-IPO equity - 2015
$25,500,000
Venture capital (Series C) - 2011
Sofinnova Partners Alto Invest ALK Abelló +2
Team Size
1–10
Employees
Location
Headquarters
MedCity News

DBV Technologies' peanut allergy patch gets FDA review

$25,500,000 Venture capital (Series C)
VentureWire

DBV Technologies Raises $25.5M Series C For Peanut Allergy Patch

$281,500,000 Post-IPO equity
FinSMEs

DBV Technologies Closes $281.5M Public Offering

$2,700,000 Venture capital
VentureWire

DBV Raises Additional $2.7M To Develop Peanut Allergy Vaccine